Targovax to rebrand as Circio, an innovator in next generation circular RNA therapeutics
· The name Circio encapsulates the strategic shift to focus on the innovative, proprietary circular RNA (circRNA) platform · circRNA has the potential to outperform mRNA, and Circio’s pipeline is initially targeting cancer, with plans to rapidly expand into vaccines and gene therapy · International patent applications covering Circio’s vector delivery technology and the therapeutic concept in cancer have been filed · Circio Holding ASA will assume the Targovax ASA listing on Oslo stock exchange under the ticker CRNAOslo, Norway, 19 April 2023 - Targovax ASA (OSE: TRVX) today